Treatment of patients with relapsed or refractory diffuse large B-cell lymphoma in the Czech Republic in 2025
Authors:
D. Belada 1; K. Polgárová 2
Authors‘ workplace:
IV. interní hematologická klinika LF UK a FN Hradec Králové
1; I. interní klinika VFN v Praze
2
Published in:
Transfuze Hematol. dnes,31, 2025, No. Ahead of Print, p. 1-9.
Category:
Original Papers
doi:
https://doi.org/10.48095/cctahd202522
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2025 Issue Ahead of Print
- What FVIII Levels Are Ideal for Preventing Bleeding in Hemophilia A?
- Cost Effectiveness of FVIII Substitution Versus Non-Factor Therapy for Hemophilia A
- Vascular Disease in the Gradually Aging Population of Hemophiliacs: An Underestimated Problem?
- Prognostic Significance of Subclinical Joint Changes on MRI in Hemophilia
- Immunotolerance is still the goal of management of hemophilia A with inhibitor in the era of non-factor therapy
Most read in this issue
- Recommendations for chronic lymphocytic leukaemia dia gnosis and therapy
- Antithrombotic prophylaxis for women in pregnancy, childbirth and the postpartum period
- Is long-term administration of interferons in polycythaemia vera associated with risks?
- MYC gene and its abnormalities with a focus on aggressive B-cell lymphomas